TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from bioAffinity Technologies, Inc. ( (BIAF) ) is now available.
On December 3, 2025, bioAffinity Technologies announced that it will present a poster at the American Cancer Society National Lung Cancer Roundtable on December 8, 2025. The poster highlights the successful use of CyPath® Lung, a noninvasive sputum-based flow cytometry test, in identifying Stage 1A lung cancer in patients with atypical presentations. This development underscores the test’s potential to provide clarity in complex diagnostic scenarios, potentially reducing the need for invasive procedures and improving early-stage lung cancer diagnosis.
The most recent analyst rating on (BIAF) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.
Spark’s Take on BIAF Stock
According to Spark, TipRanks’ AI Analyst, BIAF is a Underperform.
The overall stock score for bioAffinity Technologies, Inc. is primarily impacted by its poor financial performance and bearish technical indicators. The company’s negative profitability and cash flow issues are significant concerns. Additionally, the stock’s technical indicators suggest a continued downward trend, and the valuation metrics do not offer any compensating strengths.
To see Spark’s full report on BIAF stock, click here.
More about bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. is a biotechnology company focused on advancing noninvasive diagnostics for lung cancer and other lung diseases. Their primary product, CyPath® Lung, is a noninvasive test with high sensitivity, specificity, and accuracy for detecting early-stage lung cancer. The test is marketed as a Laboratory Developed Test by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies.
Average Trading Volume: 2,888,939
Technical Sentiment Signal: Sell
Current Market Cap: $6.16M
For an in-depth examination of BIAF stock, go to TipRanks’ Overview page.